The role of opioid receptor antagonists in the treatment of opioid-induced constipation: A review

Advances in Therapy

Volumn 27, Issue 10, 2010, Pages 714-730

  Leppert, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Constipation; Laxatives; Opioid receptor antagonists; Opioid induced constipation; Opioids; Treatment

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BISACODYL; BUPRENORPHINE; CODEINE; DIHYDROCODEINE; DOCUSATE SODIUM; DOMPERIDONE; FENTANYL; HYDROMORPHONE; LACTULOSE; LAXATIVE; LIQUID PARAFFIN; MACROGOL; METHADONE; METHYLCELLULOSE; METOCLOPRAMIDE; MORPHINE; NALMEFENE; NALOXONE; NALOXONE PLUS OXYCODONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OPIATE ANTAGONIST; OXYCODONE; PICOSULFATE SODIUM; PLACEBO; SURFACTANT; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG DERIVATIVE; NARCOTIC ANTAGONIST; OPIATE RECEPTOR; QUATERNARY AMMONIUM DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANAMNESIS; CANCER PAIN; CHRONIC PAIN; COLLAPSE; CONSTIPATION; DEFECATION; DIARRHEA; DIETARY FIBER; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; MASSAGE; NAUSEA; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; DRUG ANTAGONISM; DRUG COMBINATION;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; HUMANS; LAXATIVES; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OXYCODONE; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID;

EID: 79952116743     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0063-0     Document Type: Review

References (80)

1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S-18S.
2. Larkin PJ, Sykes NP, Centeno C, et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008;22:796-807.
3. Sykes N. The pathogenesis of constipation. J Support Oncol. 2006;4:213-218.
4. Sykes N. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998;12:375-382. (Pubitemid 28454405)
5. Leppert W, Kozikowska J, Luczak J, Glowacka A, Malinger S. Objawy ze strony ukladu pokarmowego u chorych z zaawansowana choroba nowotworowa. (Gastrointestinal symptoms in patients with advanced cancer). Nowa Med. 2000;97:18-39.
6. Leppert W, Dzierzanowski T, Cialkowska-Rysz A, Jarosz J, Pyszkowska J, Stachowiak A. Postepowanie u chorych z zaparciem stolca w medycynie paliatywnej - zalecenia Grupy Roboczej Ekspertow Polskiego Towarzystwa Medycyny Paliatywnej. (The management of constipation in palliative medicine - recommendations of the Expert Working Group of the Polish Association for Palliative Medicine). Medycyna Paliatywna. 2009;1:1-10.
7. Sykes NP. Constipation and diarrhoea. In: Doyle D, Hanks G, Cherny N, Calman K, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press; 2004: 483-496.
8. Benson AB, Stein R. Diarrhoea and constipation: supportive oncology management. In: Ettinger DS, ed. Supportive Care in Cancer Therapy. New York: Humana Press; 2009:213-225.
9. Mancini I, Bruera E. Constipation. In: Ripamonti C, Bruera E, eds. Gastrointestinal Symptoms in Advanced Cancer Patients. Oxford: Oxford University Press; 2004:193-206.
10. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain. 2006;10:209-217. (Pubitemid 43255207)
11. Meissner W, Leyendecker P, Meuller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56-64.
12. Leyendecker P, Hopp M, Bosse B, et al. Bowel Function Index (BFI), a new validated questionnaire for assessing opioid induced constipation. Proceedings of the 12th IASP World Congress on Pain; August 17-22, 2008; Glasgow, Scotland, UK.
13. Leppert W, Majkowicz M. Ocena analgezji i objawow niepozadanych tramadolu i dihydrokodeiny o kontrolowanym uwalnianiu u chorych z bolem nowotworowym - na podstawie zmodyfikowanej skali ESAS. (Assessment of analgesia and adverse effects of controlled release tramadol and dihydrocodeine in patients with cancer pain - based on a modified ESAS). Wspolcz Onkol. 2008;12:246-254.
14. Ueberral MA, Mueller-Schwefe G. Opioid-induced constipation - a frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain. 2006;10:S172.
15. Reimer K, Hopp M, Zenz M, et al. Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach. Pharmacology. 2009;83:10-17.
16. Davis MP. The opioid bowel syndrome: a review of pathophysiology and treatment. J Opioid Manage. 2005;1:153-161.
17. Holzer P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007;16:181-194. (Pubitemid 46206632)
18. Holzer P. Opioids and opioid receptors in the myenteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361: 192-195. (Pubitemid 38609249)
19. Shook JE, Pelton JT, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther. 1987;243:492-500. (Pubitemid 18011529)
20. Porecca F, Cowan A, Raffa RB, Tallarida RJ. Ketazocines and morphine: effects on gastrointestinal transit after central and peripheral administration. Life Sci. 1983;32:1785-1790. (Pubitemid 13122673)
21. Parolado D, Sala M, Gori E. Effect of intracerebroventricular administration of morphine upon intestinal motility in rat and its antagonism with naloxone. Eur J Pharmacol. 1977;46:329-338. (Pubitemid 8240486)
22. Stewart JJ, Weisbrodt NW, Burks TF. Central and peripheral action of morphine on intestinal transit. J Pharmacol Exp Ther. 1978;205:547-555. (Pubitemid 8393076)
23. Thörn SE, Wattwil M, Lindberg G, Säwe J. Systemic and central effects of morphine on gastrointestinal motility. Acta Anaesthesiol Scand. 1996;40:177-186. (Pubitemid 26063250)
24. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332-2343. (Pubitemid 351749157)
25. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39-46.
26. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16(suppl. 2):181-194.
27. Klaschik E, Nauck F, Ostgathe C. Constipation - modern laxative therapy. Support Care Cancer. 2003;11:679-685. (Pubitemid 37432623)
28. Bruera E, Brenneis C, Michand M, MacDonald N. Continuous subcutaneous infusion of metoclopramide for treatment of narcotic bowel syndrome. Cancer Treat Rep. 1987;71:1121-1122. (Pubitemid 18002237)
29. Basta S, Anderson DL. Mechanisms and management of constipation in the cancer patient. J Pharmaceut Care Pain Symptom Control. 1998;6:21-40. (Pubitemid 28495399)
30. Potter J, Wagg A. Management of bowel problems in older people: an update. Clin Med. 2005;5: 289-295. (Pubitemid 40943120)
31. Mumford SP. Can high fibre diets improve the bowel function in patients on radiotherapy ward? In: Twycross RG, Lack SA, eds. Control of Alimentary Symptoms in Far Advanced Cancer. Edinburgh: Churchill Livingstone; 1986:183.
32. Sykes NP. Current approaches to the management of constipation. Cancer Surv. 1994;21:137-146. (Pubitemid 24355818)
33. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998;6:356-364. (Pubitemid 28337126)
34. Sykes NP. A clinical comparison of laxatives in a hospice. Palliat Med. 1991;5:307-314.
35. Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006;4:CD003448.
36. Holzer P, Ahmedzai SH, Niederle N, et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manage. 2009;5:145-195.
37. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304-315. (Pubitemid 44502005)
38. Leppert W. Postepy w leczeniu farmakologicznym bolu nowotworowego analgetykami opioidowymi. (Progress in pharmacological pain treatment with opioid analgesics). Wspolcz Onkol. 2009;13: 66-73.
39. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage. 1997;13:254-261. (Pubitemid 27240678)
40. Haazen L, Noorduin H, Megens A, Meert T. The constipation-inducing potential of morphine and transdermal fentanyl. Eur J Pain. 1999; 3(suppl. A):9-15. (Pubitemid 29292685)
41. Hunt R, Fazekas B, Thorne D, Brooksbank M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 1999;18:111-119. (Pubitemid 29409439)
42. Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008;11:492-502.
43. Bach V, Kamp-Jensen M, Jensen N-H, Eriksen J. Buprenorphine and sustained release oral morphine - effect and side-effects in chronic use. Pain Clin. 1991;4:87-93.
44. Mancini IL, Hanson J, Neumann CM, Bruera E. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med. 2000;3:49-56. (Pubitemid 30262887)
45. Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. J Pain Symptom Manage. 1999;18:303-309. (Pubitemid 29469709)
46. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19:2898-2904. (Pubitemid 32538200)
47. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage. 1999;18:174-179. (Pubitemid 29459122)
48. Duggan AK. The cost of constipation in morphine patients and the economic possibilities with tramadol. Br J Med Econom. 1995;9:21-29.
49. Leppert W. Analgesic efficacy and side effects of oral tramadol and morphine administered orally in the treatment of cancer pain. Nowotwory. 2001;51:257-266. (Pubitemid 32937401)
50. Wirz S, Witmmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737-743.
51. Yuan CS. Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side effects. J Support Oncol. 2004;2:111-122.
52. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135-144. (Pubitemid 26110994)
53. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48-53. (Pubitemid 34093880)
54. Meissner W, Schimdt U, Hartmann M, et al. Oral naloxone reverses opioid-induced constipation. Pain. 2000;84:105-109.
55. Glass PS, Jhaveri RM, Smith LR. Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg. 1994;78:536-541. (Pubitemid 24079380)
56. Cheskin LJ, Chami TN, Johnson RE, et al. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. 1995;39:151-154.
57. Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62:1159-1167. (Pubitemid 351977620)
58. Anon. Oxycodone/naloxone prolonged release tablets, questions and answers. In: Paineurope supplement. London: Haymarket Medical Imprint, 174 Hammersmith Road, W6 7JP, UK; 2009 (Feb): 3-10. Available at: www.paineurope.com. Item code UK/TAR-08053.
59. Kalso E. Oxycodone. J Pain Symptom Manage. 2005;29(5S):S47-S56.
60. Biancofiore G. Oxycodone controlled release in cancer pain management. Therap Clinic Risk Manage. 2006;2:228-234.
61. Fishman J, Roffwarg H, Helman L. Disposition of naloxone-7,8-3H in normal and narcotic-dependent men. J Pharmacol Exp Ther. 1973;187:575-580.
62. Müller-Lissner S, Leyendecker P, Hopp M, Ruckes C, Fleischer W, Reimer K. Oral prolonged release (PR) oxycodone/naloxone combination reduces opioid-induced bowel dysfunction (OIBD) in patients with severe chronic pain. Eur J Pain. 2007;11:Abstract 189.
63. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain. 2008;9:1144-1154.
64. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24: 3503-3512.
65. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64:763-774.
66. Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe nonmalignant chronic pain: a randomized controlled trial. Expert Opin Pharmacother. 2009;10:531-453.
67. Schang JC, Devroede G. Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol. 1985;80:407-411. (Pubitemid 15080755)
68. Shaiova L, Rim F, Friedman D, Jahdi M. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. Palliat Support Care. 2007;5: 161-166.
69. Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral clinical methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 1997;61:467-475. (Pubitemid 27195949)
70. Yuan CS, Foss JF, O'Connor M J, Toledano A, Roizen MF, Moss J. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000;67:388-404.
71. Abarca FM, Saclarides TJ, Brand MI. A review of the treatment of opioid-induced constipation with methylnaltrexone bromide. Clinical Medicine Insights: Therapeutics. 2010;2:53-60.
72. Portenoy RK, Thomas J, Moehl Boathwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35:458-468. (Pubitemid 351601995)
73. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38:683-690.
74. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. 2007;34:547-565. (Pubitemid 350001379)
75. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother. 2007;41:984-993.
76. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000;283:367-372. (Pubitemid 30051755)
77. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized trial. J Pain. 2005;6:184-192. (Pubitemid 40365022)
78. US Food and Drug Administration. FDA approves Entereg to help restore bowel function following surgery. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116899.htm. Accessed May 21, 2010.
79. McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med. 2008;9:634-659.
80. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008;2:CD006332.